NOS2 (Ab-151) Antibody

What is NOS2/iNOS and what cellular functions does it regulate?

NOS2 (inducible nitric oxide synthase) is a 1153-amino acid protein encoded by the NOS2 gene in humans. It functions as a 131 kDa enzyme primarily involved in nitric oxide (NO) production during inflammation. The protein plays critical roles in cellular responses to lipopolysaccharides and broader inflammatory response pathways. Within cells, NOS2 is predominantly localized to the cytoplasm and undergoes ubiquitination as a key post-translational modification .

Unlike constitutive nitric oxide synthases, iNOS generates micromolar levels of NO in response to cytokine stimulation, contributing significantly to immune responses and potentially to tumorigenesis. This unique capacity for sustained high-output NO production makes it a valuable target in both immunological and cancer research.

In which tissues is NOS2 primarily expressed?

NOS2 demonstrates a distinct tissue expression profile that includes:

• Liver

• Retina

• Bone cells

• Airway epithelial cells in lungs

This tissue distribution informs experimental design when selecting appropriate cellular models for NOS2 research . When working with tissue-specific applications, researchers should validate antibody performance in their particular target tissue, as expression levels may vary significantly across different cell types.

What are the common experimental applications for NOS2 (Ab-151) antibody?

NOS2 (Ab-151) antibody has been validated for multiple experimental techniques:

The antibody demonstrates reactivity with human and mouse samples, making it suitable for comparative studies across these species . When transitioning between different experimental applications, optimization of antibody concentration is essential for achieving specific signal while minimizing background.

What controls should be included when validating NOS2 (Ab-151) antibody for experimental use?

For rigorous antibody validation, researchers should implement:

• Positive Control: RAW264.7 cells are recommended as a positive control sample, particularly when stimulated with LPS and IFN-γ to upregulate NOS2 expression .

• Negative Controls: Include samples known to lack NOS2 expression or use NOS2 knockout models.

• Peptide Competition Assay: Preabsorb the antibody with immunizing peptide to confirm signal specificity. Studies have demonstrated that staining of colon carcinoma tissues shows strong cytoplasmic iNOS signal that can be effectively blocked by preabsorption with the immunizing peptide.

• Cross-Reactivity Assessment: For phospho-specific antibodies targeting NOS2, confirm lack of cross-reactivity with non-phosphorylated iNOS. For example, the phospho-specific antibody PAB29225 has been validated to show no cross-reactivity with non-phosphorylated forms.

These controls ensure experimental rigor and reproducibility when working with NOS2 antibodies in research settings.

How should samples be prepared to optimize NOS2 detection in Western blot applications?

For optimal Western blot detection of NOS2 using Ab-151 antibody:

• Protein Extraction: Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors (particularly important when studying phosphorylated forms).

• Sample Preservation: Store lysates at -20°C with 50% glycerol in PBS (pH 7.3) to maintain protein integrity. Avoid repeated freeze-thaw cycles that may degrade the target protein .

• Loading Control: Include appropriate loading controls (β-actin, GAPDH) to normalize NOS2 expression levels.

• Denaturation Parameters: Heat samples at 95°C for 5 minutes in Laemmli buffer containing SDS and β-mercaptoethanol to ensure complete protein denaturation.

• Antibody Dilution: Begin with a 1:500 dilution and optimize as needed for your specific sample type and protein load .

This methodical approach maximizes sensitivity while maintaining specificity when detecting NOS2 in complex biological samples.

How can NOS2 (Ab-151) antibody be applied to investigate the role of phosphorylation in modulating NOS2 activity?

Phosphorylation at tyrosine 151 (Y151) represents a critical post-translational modification that modulates NOS2 activity. To investigate this regulatory mechanism:

• Phospho-specific Detection: Utilize phospho-specific antibodies directed against Y151 in parallel with total NOS2 detection to assess phosphorylation status.

• Phosphatase Treatment: Compare phosphatase-treated and untreated samples to confirm phosphorylation-dependent signals.

• Kinase Inhibitor Studies: Apply relevant kinase inhibitors to determine pathways regulating NOS2 phosphorylation.

• Mutational Analysis: Express wild-type versus Y151F mutant NOS2 to evaluate functional consequences of phosphorylation.

This multi-faceted approach enables researchers to dissect the mechanistic details of how phosphorylation events regulate NOS2 activity in different cellular contexts.

How should researchers interpret NOS2 expression patterns in cancer tissue samples?

When analyzing NOS2 expression in cancer tissues:

• Subcellular Localization: Strong cytoplasmic iNOS signal is characteristic in positive samples. Note any unusual localization patterns that may indicate altered function.

• Cancer Subtype Correlation: Elevated NOS2 expression has been documented in various cancer types with distinct patterns:

  • Higher expression in mucinous adenocarcinoma subtypes of colorectal cancer

  • Increased levels in right-sided versus left-sided colorectal tumors

  • Strong correlation with poor survival in estrogen receptor-negative (ER-) breast tumors

• Pathway Integration: Analyze NOS2 expression in context with Akt pathway activation markers to assess potential contributions to tumor aggressiveness.

• Quantification Methods: Apply standardized scoring systems (H-score, Allred score) for consistent quantification across samples.

This contextual interpretation provides deeper insights into how NOS2 contributes to tumor biology beyond mere detection of expression.

What methodological approaches can resolve contradictory findings in NOS2 expression studies?

When faced with contradictory results regarding NOS2 expression:

• Antibody Validation: Verify antibody specificity through multiple techniques (Western blot, IHC, IF) and appropriate controls.

• Tissue Preservation Variables: Consider how fixation methods and processing times affect epitope accessibility. Compare results using frozen versus paraffin-embedded tissues.

• Cell-Specific Expression: Utilize co-staining with cell-type markers to identify specific populations expressing NOS2, as expression may be heterogeneous within samples.

• Induction Status: Document treatment conditions, as NOS2 is inducible and expression varies dramatically based on inflammatory status.

• Genetic Variation: Consider the impact of NOS2 polymorphisms (such as SNP rs2297518) on expression levels and antibody binding, particularly when comparing across different patient populations.

This systematic approach helps resolve apparent contradictions by accounting for technical and biological variables affecting NOS2 detection.

How can NOS2 (Ab-151) antibody be applied to investigate cancer progression mechanisms?

NOS2 antibodies enable several approaches to investigate cancer mechanisms:

• Transcriptional Profiling Correlation: Combine IHC data with transcriptomic analysis to identify NOS2-associated gene signatures, particularly in basal-like breast cancer where high iNOS activity promotes characteristic transcriptional patterns.

• Metastatic Potential Assessment: Examine the relationship between NOS2 expression and markers of invasion/metastasis to evaluate its prognostic value.

• Therapeutic Response Prediction: Compare NOS2 levels before and after treatment to identify potential predictive biomarkers for response.

• Tumor Microenvironment Analysis: Co-stain for immune cell markers alongside NOS2 to assess inflammatory microenvironment interactions.

These approaches leverage NOS2 antibodies to generate mechanistic insights into cancer biology and potential therapeutic targets.

What considerations are important when investigating NOS2 in immune regulation using the Ab-151 antibody?

When studying NOS2 in immune contexts:

• B Cell Response Analysis: NOS2 has been implicated in regulating B cell activating factor (BAFF) expression. In the absence of NO produced by NOS2, T-independent type 2 (TI-2) antibody responses are upregulated, affecting peritoneal B1 B cells, marginal zone B cells, and some splenic myeloid cells .

• Inflammatory Stimulus Standardization: Document precise LPS concentration, timing, and additional cytokines used when comparing NOS2 induction across experimental conditions.

• Species Differences: Account for significant differences in NOS2 regulation between human and mouse systems when designing cross-species comparisons.

• Baseline vs. Induced Expression: Distinguish between constitutive low-level expression and stimulus-induced upregulation in different immune cell populations.

These methodological considerations ensure accurate interpretation of NOS2's complex roles in immune regulation .

How can researchers optimize signal-to-noise ratio when using NOS2 (Ab-151) antibody in immunohistochemistry?

To improve IHC signal specificity:

• Antigen Retrieval Optimization: Test multiple retrieval methods (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0) to determine optimal epitope exposure.

• Blocking Protocol Refinement: Extend blocking steps (5% BSA or 10% normal serum from antibody host species) to minimize non-specific binding.

• Antibody Titration: Perform systematic dilution series (starting with 1:50 - 1:200 range) to identify optimal concentration for specific tissue types .

• Incubation Parameters: Compare overnight incubation at 4°C versus shorter incubations at room temperature for optimal signal development.

• Detection System Selection: Compare different visualization methods (HRP-DAB, fluorescence, amplification systems) based on expression level of target.

These optimization steps enhance detection sensitivity while maintaining the specificity essential for accurate NOS2 localization and quantification.

What are the most effective approaches for multiplex detection of NOS2 alongside other inflammatory mediators?

For multiplex analysis integrating NOS2 detection:

• Antibody Compatibility Assessment: Verify that antibody host species and isotypes are compatible for simultaneous detection without cross-reactivity.

• Sequential Immunostaining: Consider sequential rather than simultaneous staining when using antibodies from the same host species.

• Spectrally Distinct Fluorophores: When using immunofluorescence, select fluorophores with minimal spectral overlap to allow clear signal separation.

• Signal Amplification Hierarchy: Apply amplification systems preferentially to lower-abundance targets while using direct detection for highly expressed markers.

• Digital Analysis Parameters: Implement sophisticated image analysis algorithms to accurately quantify co-expression patterns and subcellular localization.

These approaches enable complex co-expression studies essential for understanding NOS2's role within inflammatory networks.